Subgroup analysis of a phase 3 trial in 352 AML patients undergoing alloHCT: treosulfan-fludarabine vs reduced-intensity busulfan-fludarabine improved 24-month event-free survival (65% vs 53%) and lowered extensive chronic GvHD (15.1% vs 28.1%).
Secondary analysisn = 352
Stölzel et al. GvHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial